Cargando…
Belinostat exerts antitumor cytotoxicity through the ubiquitin‐proteasome pathway in lung squamous cell carcinoma
There have been advances in personalized therapy directed by molecular profiles in lung adenocarcinoma, but not in lung squamous cell carcinoma (SCC). The lack of actionable driver oncogenes in SCC has restricted the use of small‐molecule inhibitors. Here, we show that SCC cell lines displayed diffe...
Autores principales: | Kong, Li R., Tan, Tuan Z., Ong, Weijie R., Bi, Chonglei, Huynh, Hung, Lee, Soo C., Chng, Wee J., Eichhorn, Pieter J. A., Goh, Boon C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5537703/ https://www.ncbi.nlm.nih.gov/pubmed/28397399 http://dx.doi.org/10.1002/1878-0261.12064 |
Ejemplares similares
-
Belinostat and panobinostat (HDACI): in vitro and in vivo studies in thyroid cancer
por: Chan, Daniel, et al.
Publicado: (2013) -
Anti-multiple myeloma potential of resynthesized belinostat derivatives: an experimental study on cytotoxic activity, drug combination, and docking studies
por: Nguyen, Hong Phuong, et al.
Publicado: (2022) -
Repurposing Belinostat for Alleviation of Atopic Dermatitis
por: Quah, Shan, et al.
Publicado: (2021) -
Belinostat for Relapsed or Refractory Peripheral T-Cell Lymphoma
por: Hood, Katelyn, et al.
Publicado: (2016) -
MicroRNA: Important Player in the Pathobiology of Multiple Myeloma
por: Bi, Chonglei, et al.
Publicado: (2014)